All News

After a long hiatus, research in psychedelic medicine is progressing rapidly. With the potential approval of MDMA in the near future, what role will pharmacists play in integrating these new therapies into treatment plans?

Since a 2019 measles outbreak, the CDC has seen an increasing number of cases in the US.

Although over 38 million people in the US have diabetes, continuous glucose monitor (CGM) uptake is low. Community pharmacists are uniquely positioned to promote uptake due to their frequent interactions with patients and expertise in chronic condition counseling.

The CDC addressed an HPAI A(H5N1) virus infection reported by a commercial dairy farmer in Texas.

Governor Glenn Youngkin vetoed bills HB570 and SB274 that would have allowed the state to establish its first Prescription Drug Affordability Board.

“Every pharmacist raises their hand and takes an oath before they graduate to put patients first,” said Bruce Berger, PhD, FAPhA. “But what happens when you exist in an environment every single day where that’s impossible?”

Japan’s health ministry has issued a warning to consumers regarding red yeast rice dietary supplements containing a red species of mold after 5 people died and more were hospitalized after consumption.

See what's trending in pharmacy with a preview the Drug Topics April issue.

Researchers addressed pharmacists’ role in mitigating drug shortages.

With drug price negotiations for 10 drugs through the Inflation Reduction Act (IRA) set to take effect in 2026, researchers simulated the extent of Medicare savings.

Vistagen has enrolled the first participant in the PALISADE-3 phase 3 trial of fasedienol for the treatment of social anxiety disorder.

The drug was previously approved in 2009 to treat schizophrenia.

It can be hard to look away from a once in a lifetime total eclipse, but it’s important to understand the risks that come with viewing.

This year’s conference, which is being held April 4 to 6 in San Diego, California, features talks from industry experts on developments in the pharmacy field, actionable skills, and informative CE sessions.

Priovant Therapeutics said that it intends to initiate a phase 3 program of brepocitinib in the second half of this year.

Rejoyn from Otsuka Pharmaceutical and Click Therapeutics is a 6-week program that helps enhance cognitive control of emotions through brief therapy lessons and training exercises.

In comparison with the traditional volume-based pharmacy model, the membership model decreases financial barriers while increasing customer-pharmacist relationships.

The can’t-miss event on April 13 features speakers and CE sessions focused on elevating patient-centric care.

According to Anita Jacobson, PharmD, pharmacists should actively facilitate access to harm reduction programs by providing information and resources, ensuring the person who uses drugs doesn’t have to navigate the landscape on their own.

It’s important that pharmacists continuously revise their counseling as new information about substances such as xylazine, levamisole, and phenacetin emerges, said Anita Jacobson at this year’s American Pharmacists Association Annual Meeting & Exposition.

Check out a recap of important pharmacy news you might’ve missed this week, dispensed in small doses.

Researchers found various reasons for why individuals chose a specific pharmacy and how they purchase OTC medication.

Thanks to the Inflation Reduction Act, Medicare Part B coinsurance rates will lower if drug prices rise faster than the rate of inflation.

The approval of vadadustat (Vafseo) from Akebia Therapeutics was based on data from the phase 3 INNO2VATE program.

Following quality concerns voiced by the FDA regarding plastic syringes made in China, medical technology company BD has announced it will increase its production of plastic syringes in the US.

This week, a divided America watched as the Supreme Court heard oral arguments regarding whether to reinstate restrictions on accessing mifepristone, an essential drug used in medication abortion.

Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.

At APhA 2024, 2 posters looked into how collaboration between physicians and community pharmacists is crucial when it comes to opioid prescriptions, and current opioid use patterns among older adults.